{"id":"NCT00461591","sponsor":"Spectrum Pharmaceuticals, Inc","briefTitle":"Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)","officialTitle":"A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single Dose Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer (Protocol SPI-611)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2012-01","completion":"2012-01","firstPosted":"2007-04-18","resultsPosted":"2017-08-15","lastUpdate":"2021-03-30"},"enrollment":802,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bladder Cancer"],"interventions":[{"type":"DRUG","name":"Apaziquone","otherNames":["EOquin®, Qapzola"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"PROCEDURE","name":"TURBT","otherNames":[]}],"arms":[{"label":"Apaziquone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus those who received TURBT plus placebo.","primaryOutcome":{"measure":"Recurrence Rate at 2 Years","timeFrame":"2 years","effectByArm":[{"arm":"Apaziquone","deltaMin":112,"sd":null},{"arm":"Placebo","deltaMin":121,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1068"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":17},"locations":{"siteCount":74,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":93,"n":406},"commonTop":["Dysuria","Urinary tract infection","Haematuria","Pollakiuria","Micturition urgency"]}}